NeuroPace, Inc.
NeuroPace, Inc.
Your view on NPCE
Overview
What the company does, where it operates, and who runs it.
About NeuroPace, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Joel D. Becker
- Headquarters
- 455 North Bernardo Avenue, Mountain View, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Joel D. Becker
- Headquarters
- 455 North Bernardo Avenue, Mountain View, CA, US
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source.
The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for NeuroPace, Inc., and the rating behind it. NPCE last traded at $14.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for NeuroPace, Inc.. Starting points for NeuroPace, Inc.: EPS -$0.56, beta 1.95 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for NeuroPace, Inc.. NeuroPace, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for NeuroPace, Inc.. Trailing twelve-month EPS for NeuroPace, Inc. stands at -$0.56. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for NeuroPace, Inc.. NeuroPace, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
NeuroPace, Inc. valued side by side against its closest peers. NeuroPace, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold NeuroPace, Inc., and how their positions are changing. At a $478.7M market value, institutional positions materially move NeuroPace, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by NeuroPace, Inc. executives and directors. Shares of NeuroPace, Inc. have traded between $7.56 and $18.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming NeuroPace, Inc.. NeuroPace, Inc. is a $478.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming NeuroPace, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for NeuroPace, Inc.. Coverage tracks NeuroPace, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.